Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.
Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development program for the treatment of obesity,…
Biophytis announces its participation to the BIOMED FORUM investor conference Biophytis announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris. The Biomed Forum is the annual event dedicated to the healthcare sector, fostering connections between biotech or medtech companies and institutional…
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China Biophytis today announces the signing of a co-development agreement with AskHelpU, the largest patient association in China for those affected by amyotrophic lateral sclerosis (ALS). Fullscreen Mode
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 Biophytis announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in China for its most promising and…
Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program Cash contribution of €2.5 million from existing and new investors to finance the clinical development of BIO101 in obesity Conversion into equity of debt for up to €6.1 million strengthening the balance sheet…
Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction Biophytis announces today that the listing of its ordinary shares and share warrants on the Euronext Growth market, and its American Depositary Shares (ADS) on the OTC market, will be…
Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference Will participate also in the following events: Sachs Conference – BioPharma Obesity Innovation Forum The BIO@JPM Week Conference Biophytis announces its participation in the inaugural BioPharma Obesity Innovation Forum (#Sachs_BOIF) on January 11, 2025, in San Francisco,…
Biophytis showcased the OBA program in obesity at the 17th SCWD international congress Biophytis took part in the 17th international SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) congress, a flagship event bringing together experts from around the world to share innovations on sarcopenia, cachexia and muscle wasting including weight…
Biophytis its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8, 2024, in Washington, D.C. As part of the congress, Biophytis will host an Obesity Investor Call on the topic: “GLP-1 RA weight loss therapy-induced muscle…
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis publishes its financial results for the first half of 2024 and provides an update on the company’s key achievements. Stanislas Veillet, CEO of Biophytis, commented: “We are particularly pleased with the progress made in the first…
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Biophytis announces the deployment of its partnership strategy in Asia. To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for…
Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) for its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The primary objective of…
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Our lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.
BIOPHYTIS ON THE STOCK MARKET
Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015.
ISIN FR001400OLP5
Ticker: ALBPS
Type of listing: continuous
Total number of shares at 31/01/2025: 15,856,261
1 ADR = 10 shares
Number of voting rights at 31/01/2025: 15,886,577
Eligible for PEA and PEA-PME equity saving plans
Click here for live stock price